Cellceutix Corp. (CTIX.OB) reported that it has been conducting meetings with manufacturers to synthesize and formulate its lead psoriasis drug, Prurisol, for a Phase 2/3 clinical trial.
Cellceutix said the U.S. Food and Drug Administration recently told the company that an application for a 505(b)(2) designation for Prurisol would be an acceptable approach; allowing the Company to advance Prurisol immediately into advanced stages of clinical trials.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.